Solid Organ Transplantation After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective,Multicenter Study of the EBMT |
| |
| Authors: | C. Koenecke B. Hertenstein J. Schetelig A. Van Biezen E. Dammann A. Gratwohl A. Ganser M. Schleuning M. Bornhäuser N. Jacobsen N. Kröger D. Niederwieser T. De Witte T. Ruutu |
| |
| Affiliation: | 1. Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem‐Cell Transplantation, Hannover, Germany;2. Klinikum Bremen Mitte, Medizinische Klinik I, Bremen, Germany;3. University Hospital Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany;4. Chronic Leukemia Working Party, Leiden University Medical Center, Department of Medical Statistics and Bioinformatics, Leiden, the Netherlands;5. University Hospital Basel, Department of Hematology, Basel, Switzerland;6. Deutsche Klinik für Diagnostik, Wiesbaden, Germany;7. Righospitalet Copenhagen, Department of Haematology, Copenhagen, Denmark;8. University Medical Center Hamburg‐Eppendorf, Department of Stem Cell Transplantation, Hamburg, Germany;9. University of Leipzig, Division of Haematology and Oncology, Leipzig, Germany;10. Radboud University‐Nijmegen Medical Center, Department of Hematology, Nijmegen, The Netherlands;11. Helsinki University Central Hospital, Department of Medicine, Helsinki, Finland |
| |
| Abstract: | To analyze the outcome of solid organ transplantation (SOT) in patients who had undergone allogeneic hematopoietic stem cell transplantation (HSCT), a questionnaire survey was carried out within 107 European Group of Blood and Marrow Transplantation centers. This study covered HSCT between 1984 and 2007 in Europe. Forty‐five SOT in 40 patients were reported. Fifteen liver, 15 renal, 13 lung, 1 heart and 1 skin transplantations were performed in 28 centers. Overall survival (OS) of patients after SOT was 78% at 5 years (95% confidence interval [CI], 64% to 92%). OS at 5 years was 100% for renal, 71% (95% CI, 46% to 96%) for liver and 63% (95% CI, 23% to 100%) for lung transplant recipients. The 2‐year‐incidence of SOT failure was 20% (95% CI, 4% to 36%) in patients with graft‐versus‐host disease (GvHD) and 7% (95% CI, 0% to 21%) in patients without GvHD before SOT. The relapse incidence for underlying malignant diseases was 4% at 5 years (95% CI, 0% to 12%). In summary, this study shows that selected patients receiving SOT after HSCT have a remarkably good overall and organ survival. These data indicate that SOT should be considered in selected patients with single organ failure after HSCT. |
| |
| Keywords: | Heart transplantation kidney transplantation liver transplantation lung transplantation skin transplantation stem cell transplantation transplantation |
|
|
